Medtronic has officially launched its MiniMed Go smart multiple daily injection (MDI) system across Europe, marking a major step forward for people with insulin-requiring diabetes who prefer injections over pump therapy.

MiniMed Go combines the InPen smart insulin pen with the Simplera continuous glucose monitor (CGM) in one mobile app, unifying both devices on a single platform. The rollout began this month for individuals aged 7 and older, and for children 2 to 6 with adult supervision. The system offers real-time personalized insights, dose alerts, and a built-in advanced calculator that delivers continuous guidance through a smartphone app, along with new CareLink Clinic MDI reports to simplify data interpretation and support clinical conversations.

The launch follows FDA clearance in the United States last month. In Europe, CE mark approval for the Instinct sensor is still pending, which will eventually give users the option to choose between the 7-day Simplera or the Instinct’s 15‑day wear. At the same time, Medtronic’s Diabetes division is preparing to spin off as MiniMed through a recently priced IPO, while the company continues investing in next-generation insulin pumps.

MiniMed Go represents a meaningful leap in smarter, data-driven decision support for people managing diabetes with daily injections. If you want to learn more about the MiniMed Go platform, listen to our podcast episode where we spoke with Medtronic about the Instinct sensor and what users can expect from MiniMed Go.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.